COM:SAGERX
Sage Therapeutics
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.sagerx.com/ipo date
Jul 18, 2014
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III c...Show More